VITA 34 AG (GB:0NLV)
LSE:0NLV
Want to see GB:0NLV full AI Analyst Report?
0NLV Stock Chart & Stats
€6.20
€0.00(0.00%)
At close: 4:00 PM EST
€6.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.80 - €9.80
Previous CloseN/A
Volume0.00
Average Volume (3M)272.00
Market Cap
€78.44M
Enterprise Value€86.50M
Total Cash (Recent Filing)€13.05M
Total Debt (Recent Filing)€19.35M
Price to Earnings (P/E)21.1
Beta0.37
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,640,104
10 Day Avg. Volume528
30 Day Avg. Volume272
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)5.08
Price to Sales (P/S)0.87
P/FCF Ratio13.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)€92.00M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelThe subscription-like annual storage fees create a durable, predictable revenue base and high customer lifetime value. This recurring cash inflow supports long-term planning, capacity utilization and makes scaling unit economics easier as customer volumes grow over months to years.
Niche Market LeadershipEstablished specialization in umbilical cord blood storage gives structural competitive advantages: regulatory know-how, trust among families and hospital partnerships. These barriers and domain expertise sustain market share and pricing power over the medium term.
Revenue Growth MomentumMaterial revenue expansion indicates successful customer acquisition and service uptake, supporting scale economies. If sustained, this growth can improve gross margins, spread fixed costs and provide a platform for reinvestment into product offerings and partnership expansion.
Bears Say
High Financial LeverageElevated leverage increases fixed interest obligations and reduces financial flexibility, limiting the firm's ability to fund capex or weather cyclical slowdowns. Over months, this raises refinancing and solvency risk, particularly if cash generation does not strengthen.
Persistent UnprofitabilityNegative ROE and recurring net losses constrain retained earnings and limit internal funding for growth. Sustained unprofitability pressures equity value, deters investment, and forces reliance on external capital which can dilute shareholders or increase debt.
Weak Cash Flow ConversionInability to convert income into cash undermines the company's capacity to service debt, invest in capacity or fund working capital from operations. Over a multi-month horizon this may necessitate costly financing, constrain growth initiatives, and elevate liquidity risk.
0NLV FAQ
What was VITA 34 AG’s price range in the past 12 months?
VITA 34 AG lowest share price was €3.80 and its highest was €9.80 in the past 12 months.
What is VITA 34 AG’s market cap?
VITA 34 AG’s market cap is €78.44M.
When is VITA 34 AG’s upcoming earnings report date?
VITA 34 AG’s upcoming earnings report date is Apr 30, 2026 which is today.
How were VITA 34 AG’s earnings last quarter?
Currently, no data Available
Is VITA 34 AG overvalued?
According to Wall Street analysts VITA 34 AG’s price is currently Overvalued.
Does VITA 34 AG pay dividends?
VITA 34 AG does not currently pay dividends.
What is VITA 34 AG’s EPS estimate?
VITA 34 AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 AG have?
VITA 34 AG has 17,640,104 shares outstanding.
What happened to VITA 34 AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VITA 34 AG?
Currently, no hedge funds are holding shares in GB:0NLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VITA 34 Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
VITA 34 AG
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.